Literature DB >> 17341643

Dual activity of phosphorothioate CpG oligodeoxynucleotides on HIV: reactivation of latent provirus and inhibition of productive infection in human T cells.

Carsten Scheller1, Anett Ullrich, Stefan Lamla, Ulf Dittmer, Axel Rethwilm, Eleni Koutsilieri.   

Abstract

CpG oligodeoxynucleotides (CpG ODNs) bind to toll-like receptor-9 (TLR-9) and activate immune cells with antigen-presenting activity, including B cells and dendritic cells. Here we show that treatment of the latently human immunodeficiency virus (HIV)-infected T cell line ACH-2 with the CpG ODNs 2006 or 2040 triggers activation of viral gene expression, demonstrating that CpG-signaling activity can also be found in T cells. The CpG ODNs g12AAC and g12GTC had no effect on virus reactivation. In contrast to the stimulating effects on viral gene expression in latently infected cells, CpG ODNs potently suppressed HIV replication in productively infected MT4 T cells or PBLs. Inhibition of virus replication was not related to the CpG motif but similarly occurred with non-CpG phosphorothioate (PTO)-ODNs. Thus, virus inhibition was likely caused by the PTO backbone of the CpG ODNs, probably by interfering with events prior to integration of the viral cDNA into the host genome. The ability of CpG PTO-ODNs to trigger reactivation of latent HIV in combination with their antiviral activity on productive infection makes this substance class an interesting candidate for further test to asses their potential as supplements in HIV therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17341643     DOI: 10.1196/annals.1378.095

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  9 in total

Review 1.  Cancer therapies in HIV cure research.

Authors:  Thomas A Rasmussen; Jenny L Anderson; Fiona Wightman; Sharon R Lewin
Journal:  Curr Opin HIV AIDS       Date:  2017-01       Impact factor: 4.283

Review 2.  HIV Latency in Myeloid Cells: Challenges for a Cure.

Authors:  Alisha Chitrakar; Marta Sanz; Sanjay B Maggirwar; Natalia Soriano-Sarabia
Journal:  Pathogens       Date:  2022-05-24

3.  Phosphorothioate-modified oligodeoxynucleotides inhibit human cytomegalovirus replication by blocking virus entry.

Authors:  Anna Luganini; Patrizia Caposio; Santo Landolfo; Giorgio Gribaudo
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

4.  Toll-like receptor 3 activation selectively reverses HIV latency in microglial cells.

Authors:  David Alvarez-Carbonell; Yoelvis Garcia-Mesa; Stephanie Milne; Biswajit Das; Curtis Dobrowolski; Roxana Rojas; Jonathan Karn
Journal:  Retrovirology       Date:  2017-02-06       Impact factor: 4.602

5.  Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers In Vitro.

Authors:  Gabriel Ozorowski; Albert Cupo; Michael Golabek; Michelle LoPiccolo; Thomas A Ketas; Matt Cavallary; Christopher A Cottrell; P J Klasse; Andrew B Ward; John P Moore
Journal:  J Virol       Date:  2018-06-13       Impact factor: 5.103

Review 6.  Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists.

Authors:  Amanda B Macedo; Camille L Novis; Alberto Bosque
Journal:  Front Immunol       Date:  2019-10-15       Impact factor: 7.561

7.  Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients.

Authors:  Anni A Winckelmann; Lærke V Munk-Petersen; Thomas A Rasmussen; Jesper Melchjorsen; Thomas J Hjelholt; David Montefiori; Lars Østergaard; Ole S Søgaard; Martin Tolstrup
Journal:  PLoS One       Date:  2013-04-26       Impact factor: 3.240

Review 8.  Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials.

Authors:  Thomas A Rasmussen; Martin Tolstrup; Anni Winckelmann; Lars Østergaard; Ole S Søgaard
Journal:  Hum Vaccin Immunother       Date:  2013-04-01       Impact factor: 3.452

Review 9.  Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents.

Authors:  Héloïse M Delagrèverie; Constance Delaugerre; Sharon R Lewin; Steven G Deeks; Jonathan Z Li
Journal:  Open Forum Infect Dis       Date:  2016-10-07       Impact factor: 3.835

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.